The corona19 vaccine, jointly developed by Oxford University and AstraZeneca, showed an average of 70 percent immune effects as a result

The corona19 vaccine, 달토가라오케 jointly developed by Oxford University and AstraZeneca, showed an average of 70 percent immune effects as a result of early data analysis of clinical three-phase trials. According to the vaccine injection method, the effect has increased to 90 percent. An official from the Ministry of Food and Drug Safety explained, 클럽레이스 "It is difficult to disclose what data are currently being reviewed in addition to full-time data, but we usually review safety and validity even as a result of clinical tests abroad." The official said, "If AstraZeneca applies for item approval under the 'Go Rapid Program', which greatly reduces the period of clinical tests and permits, the approval can be completed within one to two months." Overseas, there are expectations that AstraZeneca's vaccine will be produced as early as Christmas. 클럽플렉스 As a result, Korean industries predict that AstraZeneca will apply for permission from the KFDA early next year.